“What I found exciting was that the extent to which a…PI-RADS 4 score saved biopsies without really affecting the likelihood of detecting clinically significant tumor,” says Stella K. Kang, MD.
In this video, Stella K. Kang, MD, discusses notable findings from the recent Radiology study, “Active Surveillance Strategies for Low-Grade Prostate Cancer: Comparative Benefits and Cost-effectiveness,” for which she served as a study author. Kang is an associate professor of radiology and population health and director of Comparative Effectiveness and Outcomes Research in the department of radiology at NYU Grossman School of Medicine, New York.
Targeted radiation plus systemic therapy combo shows promise in mHSPC
March 18th 2024"The combination of highly potent systemic therapy and targeted radiation has shown impressive results in maintaining low PSA levels after testosterone recovery, offering hope for improved outcomes in these patients, but further studies are still needed to determine the best regimen," says Amar U. Kishan, MD.
Relugolix plus radiotherapy shows safety, efficacy in prostate cancer
March 14th 2024“Remarkably, relugolix demonstrated a faster return to baseline testosterone levels compared [with] traditional therapies, a crucial aspect for patients' quality of life post-treatment," says Daniel E. Spratt, MD.